{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T03:03:18Z","timestamp":1779850998216,"version":"3.53.1"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Qualitative urine drug screens (UDSs) are essential in clinical toxicology for assessments of drug exposure and are commonly employed by emergency departments to provide rapid results that inform care. Fentanyl, a potent synthetic opioid, is of significant public health concern due to rising overdose rates. However, fentanyl is also administered clinically as an analgesic, which may result in positive UDS assessments for patients with iatrogenic exposure. Positive UDS findings may cause patient anxiety, provider confusion, and lead to medicolegal concerns in clinical settings such as labor and delivery and neonatology. As such, it is essential that UDSs are utilized appropriately and that the positivity threshold for the assay is rigorously evaluated to serve the clinical need. This study examined UDS utilization within a quaternary care system over a 1-year period. A subset of remnant urine specimens from UDSs was further analyzed using high resolution mass spectrometry (HRMS) and liquid chromatography\u2013tandem mass spectrometry (LC\u2013MS\/MS) to focus on the impact of fentanyl immunoassay cutoff concentrations in high-volume populations. At our institution, the adult emergency department (ED) had the highest number of specimens ordered (5901), while neonatal units had the least (727). Notably, fentanyl positivity rates were the highest in neonatal units at 34%. Quantitative analysis of remnant urine samples from the ED, labor and delivery (L&amp;D), and neonatal units showed higher fentanyl concentrations in the ED, indicative of illicit use, and lower concentrations in L&amp;D and neonates, consistent with analgesic administration. Raising the immunoassay cutoff from 1.0 to 5.0\u2009ng\/ml would convert iatrogenic positives to negatives while retaining illicit positives. These findings underscore the need to evaluate UDS cutoff values for improved clinical performance in different populations.<\/jats:p>","DOI":"10.1093\/jat\/bkag025","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T11:41:54Z","timestamp":1776253314000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluating the impact of fentanyl immunoassay cutoff concentrations in emergency department, maternal, and neonatal populations"],"prefix":"10.1093","volume":"50","author":[{"given":"Maxwell L","family":"Harsha","sequence":"first","affiliation":[{"name":"Department of Pathology, Johns Hopkins University School of Medicine , Baltimore, MD 21287,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Weaver","sequence":"additional","affiliation":[{"name":"Department of Pathology, Johns Hopkins University School of Medicine , Baltimore, MD 21287,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A","family":"Clarke","sequence":"additional","affiliation":[{"name":"Department of Pathology, Johns Hopkins University School of Medicine , Baltimore, MD 21287,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4546-1455","authenticated-orcid":false,"given":"Ashley R","family":"Rackow","sequence":"additional","affiliation":[{"name":"Department of Pathology, Johns Hopkins University School of Medicine , Baltimore, MD 21287,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"2026052622265960200_bkag025-B1","first-page":"12","author":"Substance Abuse and Mental Health Services, Administration","year":"2012"},{"key":"2026052622265960200_bkag025-B2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/B978-0-12-813776-5.00014-5","volume-title":"Accurate Results in the Clinical Laboratory","author":"Boyd","year":"2019","edition":"2nd edn"},{"key":"2026052622265960200_bkag025-B3","doi-asserted-by":"crossref","first-page":"2374289518811797","DOI":"10.1177\/2374289518811797","article-title":"A difficult challenge for the clinical laboratory: accessing and interpreting manufacturer cross-reactivity data for immunoassays used in urine drug testing","volume":"5","author":"Reschly-Krasowski","year":"2018","journal-title":"Acad Pathol"},{"key":"2026052622265960200_bkag025-B4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/jat\/bku075","article-title":"False-positive interferences of common urine drug screen immunoassays: a review","volume":"38","author":"Saitman","year":"2014","journal-title":"J Anal Toxicol"},{"key":"2026052622265960200_bkag025-B5","author":"Mandatory Guidelines for Federal Workplace Drug Testing Programs\u2014Authorized Testing Panels"},{"key":"2026052622265960200_bkag025-B6","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/jalm\/jfaf172","article-title":"ADLM guidance document on laboratory testing for drugs of misuse to support the emergency department","volume":"11","author":"Snozek","year":"2026","journal-title":"J Appl Lab Med"},{"key":"2026052622265960200_bkag025-B7","author":"Spencer"},{"key":"2026052622265960200_bkag025-B8","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.cll.2025.01.012","article-title":"Detection of fentanyl and fentanyl analogs","volume":"45","author":"Crews","year":"2025","journal-title":"Clin Lab Med"},{"key":"2026052622265960200_bkag025-B9","author":"Vogel","year":"2023"},{"key":"2026052622265960200_bkag025-B10","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jmsacl.2023.02.009","article-title":"Evaluating the performance of the Roche FEN2 fentanyl immunoassay and its clinical implementation: the role of LDT-based mass spectrometry testing","volume":"28","author":"Menlyadiev","year":"2023","journal-title":"J Mass Spectrom Adv Clin Lab"},{"key":"2026052622265960200_bkag025-B11","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/bja\/82.6.929","article-title":"Placental transfer of fentanyl in early human pregnancy and its detection in fetal brain","volume":"82","author":"Cooper","year":"1999","journal-title":"Br J Anaesth"},{"key":"2026052622265960200_bkag025-B12","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1093\/jalm\/jfaa027","article-title":"Rates of fentanyl positivity in neonatal urine following maternal analgesia during labor and delivery","volume":"5","author":"Novikov","year":"2020","journal-title":"J Appl Lab Med"},{"key":"2026052622265960200_bkag025-B13","doi-asserted-by":"crossref","first-page":"741.e1","DOI":"10.1016\/j.ajog.2022.11.1293","article-title":"Fentanyl in the labor epidural impacts the results of intrapartum and postpartum maternal and neonatal toxicology tests","volume":"228","author":"Siegel","year":"2023","journal-title":"Am J Obstet Gynecol"},{"key":"2026052622265960200_bkag025-B14","volume-title":"Liquid Chromatography-Mass Spectrometry Methods","author":"CLSI","year":"2022","edition":"2nd"},{"key":"2026052622265960200_bkag025-B15","doi-asserted-by":"crossref","first-page":"111287","DOI":"10.1016\/j.drugalcdep.2024.111287","article-title":"Understand the FDA-cleared fentanyl testing: A clinical evaluation of the SEFRIA fentanyl immunoassay","volume":"259","author":"Wang","year":"2024","journal-title":"Drug Alcohol Depend"},{"key":"2026052622265960200_bkag025-B16","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.1097\/ADM.0000000000001010","article-title":"False-positive fentanyl urine detection after initiation of labetalol treatment for hypertension in pregnancy: a case report","volume":"16","author":"Wanar","year":"2022","journal-title":"J Addict Med"},{"key":"2026052622265960200_bkag025-B17","doi-asserted-by":"crossref","first-page":"100733","DOI":"10.1016\/j.ajogmf.2022.100733","article-title":"Urine drug screening on labor and delivery","volume":"4","author":"Chin","year":"2022","journal-title":"Am J Obstet Gynecol MFM"},{"key":"2026052622265960200_bkag025-B18","first-page":"83","article-title":"Abnormal urine drug screens in pregnancy- opportunity for laboratory stewardship","volume":"36","author":"Chokkalla","year":"2025","journal-title":"EJIFCC"},{"key":"2026052622265960200_bkag025-B19","doi-asserted-by":"crossref","first-page":"100303","DOI":"10.1016\/j.jpi.2023.100303","article-title":"A web application to support the coordination of reflexive, interpretative toxicology testing","volume":"14","author":"Pablo","year":"2023","journal-title":"J Pathol Inform"},{"key":"2026052622265960200_bkag025-B20","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0376-8716(93)90001-7","article-title":"Punishing pregnant drug users: enhancing the flight from care","volume":"31","author":"Poland","year":"1993","journal-title":"Drug Alcohol Depend"},{"key":"2026052622265960200_bkag025-B21","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/ADM.0000000000000832","article-title":"Assessing stigma towards substance use in pregnancy: a randomized study testing the impact of stigmatizing language and type of opioid use on attitudes toward mothers with opioid use disorder","volume":"16","author":"Schiff","year":"2022","journal-title":"J Addict Med"},{"key":"2026052622265960200_bkag025-B22","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.siny.2019.01.007","article-title":"Screening for substance use in pregnancy and the newborn","volume":"24","author":"Polak","year":"2019","journal-title":"Semin Fetal Neonatal Med"},{"key":"2026052622265960200_bkag025-B23","doi-asserted-by":"crossref","first-page":"e013942","DOI":"10.1136\/bmjopen-2016-013942","article-title":"Mandated reporters\u2019 experiences with reporting child maltreatment: a meta-synthesis of qualitative studies","volume":"7","author":"McTavish","year":"2017","journal-title":"BMJ Open"},{"key":"2026052622265960200_bkag025-B24","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/ADM.0000000000000614","article-title":"Validation of the NIDA-modified ASSIST as a screening tool for prenatal drug use in an urban setting in the United States","volume":"14","author":"Oga","year":"2020","journal-title":"J Addict Med"},{"key":"2026052622265960200_bkag025-B25","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1097\/AOG.0b013e3181ed8290","article-title":"Screening for prenatal substance use: development of the substance use risk profile-pregnancy scale","volume":"116","author":"Yonkers","year":"2010","journal-title":"Obstet Gynecol"},{"key":"2026052622265960200_bkag025-B26","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/sj.jp.7211823","article-title":"Validation of the 4P\u2019s Plus\u00a9 screen for substance use in pregnancy validation of the 4P\u2019s Plus","volume":"27","author":"Chasnoff","year":"2007","journal-title":"J Perinatol"},{"key":"2026052622265960200_bkag025-B27","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jogn.2024.01.007","article-title":"Drug testing of pregnant patients","volume":"53","author":"Cleveland","year":"2024","journal-title":"J Obstet Gynecol Neonatal Nurs"},{"key":"2026052622265960200_bkag025-B28","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jogn.2022.10.002","article-title":"Drug testing practices and policies of labor and delivery units across the southeastern United States","volume":"52","author":"Byrd","year":"2023","journal-title":"J Obstet Gynecol Neonatal Nurs"},{"key":"2026052622265960200_bkag025-B29","doi-asserted-by":"crossref","first-page":"100453","DOI":"10.1016\/j.ajogmf.2021.100453","article-title":"Racial differences in indications for obstetrical toxicology testing and relationship of indications to test results","volume":"4","author":"Perlman","year":"2022","journal-title":"Am J Obstet Gynecol MFM"},{"key":"2026052622265960200_bkag025-B30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11414-011-9247-x","article-title":"Universal screening for alcohol and drug use and racial disparities in child protective services reporting","volume":"39","author":"Roberts","year":"2012","journal-title":"J Behav Health Serv Res"},{"key":"2026052622265960200_bkag025-B31","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/AOG.0000000000004786","article-title":"Redefining child protection: addressing the harms of structural racism and punitive approaches for birthing people, dyads, and families affected by substance use","volume":"140","author":"Wakeman","year":"2022","journal-title":"Obstet Gynecol"},{"key":"2026052622265960200_bkag025-B32","doi-asserted-by":"crossref","first-page":"e250908","DOI":"10.1001\/jamanetworkopen.2025.0908","article-title":"Racial equity in urine drug screening policies in labor and delivery","volume":"8","author":"Azimi","year":"2025","journal-title":"JAMA Network Open"},{"key":"2026052622265960200_bkag025-B33","doi-asserted-by":"crossref","first-page":"100313","DOI":"10.1016\/j.xagr.2024.100313","article-title":"Prolonged detection of urine norfentanyl in individuals enrolled in a medication for opioid use disorder in pregnancy and postpartum program: a case series","volume":"4","author":"Kiefer","year":"2024","journal-title":"AJOG Glob Rep"}],"container-title":["Journal of Analytical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jat\/advance-article-pdf\/doi\/10.1093\/jat\/bkag025\/68111247\/bkag025.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jat\/article-pdf\/50\/5\/bkag025\/68111247\/bkag025.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jat\/article-pdf\/50\/5\/bkag025\/68111247\/bkag025.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T02:27:06Z","timestamp":1779848826000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jat\/article\/doi\/10.1093\/jat\/bkag025\/8658822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,26]]}},"URL":"https:\/\/doi.org\/10.1093\/jat\/bkag025","relation":{},"ISSN":["1945-2403"],"issn-type":[{"value":"1945-2403","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,4,17]]},"article-number":"bkag025"}}